Question reference: S6W-23036
- Date lodged: 20 November 2023
-
Current status: Answered by Jenni Minto on 4 December 2023
Question
To ask the Scottish Government what it is doing to source the anti-diabetic medication, liraglutide, which is used to treat type 2 diabetes, in light of reports that there are severe shortages of the medication across Scotland.
Answer
The Scottish Government is aware that there are global supply issues with glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs) products, which are licensed for treating patients with type 2 diabetes, including Victoza (liraglutide). It is anticipated that supplies of all GLP-1 RAs products will be limited and intermittent until at least mid-2024.
The global shortage of GLP-1 RAs has been largely driven by increased demand, including for off-label and private online prescribing of these medicines for weight-loss; this has led to shortages for patients with Type 2 diabetes.
The supply of medicines is currently a reserved matter for the UK Government. We continue to engage with the Department for Health and Social Care (DHSC) and we will continue to press for a lasting solution to the current shortages.
The Scottish Government recognises the impact of these global shortages on people living with type 2 diabetes and their families. NHS Scotland has robust systems in place to manage medicine shortages when they arise and anyone affected by this issue should speak to their usual clinical team.